Director and 10% Owner Sells $489K in Atara Biotherapeutics Stock

summarizeSummary

The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.

check_boxKey Events

• Insider Sale

  James Huang, a Director and 10% owner, disposed of 80,554 shares of Atara Biotherapeutics common stock.

• Significant Value

  The sale amounted to $489,019, a substantial transaction for the company.

• Transaction Price

  Shares were sold at a weighted average price of $6.07 on January 12, 2026, compared to the current stock price of $4.58.

auto_awesomeAnalysis

The sale of common stock by James Huang, who serves as both a Director and a 10% owner, is a notable event for Atara Biotherapeutics. The transaction value of nearly $490,000 is substantial for a company of ATRA's size, indicating a significant reduction in insider exposure. Shares were sold at a weighted average price of $6.07 on January 12, 2026, which is notably higher than the current stock price of $4.58. Investors may interpret this as a move to lock in gains, potentially putting downward pressure on the stock.